Translocation, Genetic: Clinical Trials

8 trials for Translocation, Genetic, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

7 completed, 1 recruiting. 8 Phase 1, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 18Completed 7, Recruiting 1
Phase 22Completed 1, Recruiting 1

Follow Translocation, Genetic: new trials by email Literature Review of Translocation, Genetic trials Research Report on Translocation, Genetic

Trials (filtered) newest first · largest first

All 8 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies
CD19/CD22-CAR-transduced T cells, cyclophosphamide, fludarabine - B-NHL, B-Non Hodgkin Lymphoma
Phase 1 / Phase 2RecruitingNational Cancer Institute (NCI)1302022-12-282026-10-26
CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
CD19/CD22 CAR T-Cells, Fludarabine, Cyclophosphamide - Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, B Cell
Phase 1CompletedNational Cancer Institute (NCI)542018-03-262025-06-04
Azacitidine (AZA) in Minimal Residual Disease (MRD) Chronic Myeloid Leukemia (CML)
Azacitidine (AZA), Tyrosine kinase inhibitor (TKI), Azacitidine - Leukemia
Phase 1CompletedM.D. Anderson Cancer Center32012-08-082020-03-05
Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies
Melphalan, Fludarabine, Mycophenolate mofetil - Blood And Marrow Transplantation, Leukemia
Phase 1CompletedM.D. Anderson Cancer Center332012-07-132017-04-28
Philadelphia Chromosome Positive CML Patients Without Optimal Response or Tolerance to Bcr-Abl TKI
Radotinib - Leukemia, Leukemia, Myeloid
Phase 1 / Phase 2CompletedIl-Yang Pharm. Co., Ltd.852008-07-012018-08-29
Effect of Imatinib Mesylate and the Pharmacokinetics of Acetaminophen/Paracetamol in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
Imatinib/Acetaminophen - Chronic Myeloid Leukemia (CML)
Phase 1CompletedNovartis Pharmaceuticals122006-11-012016-04-21
Effect of Food on Bioavailability of Modified Release Formulations of Imatinib
imatinib - Healthy
Phase 1CompletedNovartis322006-09-012016-04-05
Effect of Food on Bioavailability of a Modified Release Formulation of Imatinib
imatinib - Healthy
Phase 1CompletedNovartis Pharmaceuticals162006-06-012016-04-05

Narrower conditions

Philadelphia Chromosome (8)  ·  Leukemia, Myelogenous, Chronic, BCR-ABL Positive (6)  ·  Leukemia (3)  ·  Lymphoma (3)  ·  Lymphoma, Non-Hodgkin (3)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (3)  ·  Burkitt Lymphoma (2)  ·  Leukemia, B-Cell (2)  ·  Lymphoma, B-Cell (2)  ·  Hematologic Diseases (1)  ·  Hematologic Neoplasms (1)  ·  Histiocytosis, Langerhans-Cell (1)  ·  Hodgkin Disease (1)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (1)  ·  Leukemia, Myeloid (1)

Broader conditions

Chromosome Aberrations (8)  ·  Hemic and Lymphatic Diseases (8)  ·  Neoplasms (8)  ·  Neoplasms by Histologic Type (8)  ·  Pathologic Processes (8)  ·  Pathological Conditions, Signs and Symptoms (8)  ·  Hematologic Diseases (7)  ·  Bone Marrow Diseases (6)  ·  Chronic Disease (6)  ·  Disease Attributes (6)  ·  Myeloproliferative Disorders (6)  ·  Leukemia (5)  ·  Leukemia, Myeloid (5)  ·  Immune System Diseases (3)

Interventions

Imatinib Mesylate (3)  ·  fludarabine (3)  ·  Acetaminophen (2)  ·  Cyclophosphamide (2)  ·  fludarabine phosphate (2)  ·  4-methyl-N-(3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl)-3-(4-pyrazin-2-ylpyrimidin-2-ylamino)benzamide (1)  ·  Antiemetics (1)  ·  Antilymphocyte Serum (1)  ·  Azacitidine (1)  ·  Blood Component Removal (1)  ·  Blood Specimen Collection (1)  ·  Bone Marrow Transplantation (1)  ·  Busulfan (1)  ·  Clofarabine (1)  ·  Diphenhydramine (1)

Sponsors

M.D. Anderson Cancer Center (2)  ·  National Cancer Institute (NCI) (2)  ·  Novartis Pharmaceuticals (2)  ·  Il-Yang Pharm. Co., Ltd. (1)  ·  Novartis (1)

Countries

United States (4)  ·  South Korea (2)  ·  India (1)  ·  Thailand (1)

Top investigators

Elizabeth Shpall, MD (1)  ·  IL-yang Pharm (1)  ·  Jorge Cortes, MD (1)  ·  Nirali N Shah, M.D. (1)  ·  Sara K Silbert, M.D. (1)

Results publications

PMID 24705186, PMID 25778529, PMID 34687939, PMID 34889384, PMID 35605184, PMID 37486616, PMID 38376944, PMID 42248607

NIH funding

P01CA148600 (1)